Yoshihisa Matsukawa

Dr. Yoshihisa Matsukawa

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2018 in Neurourology and Urodynamics
Verified
Journal Article
Closed access
PDF file
YMYoshihisa Matsukawa
Yoshihisa Matsukawa
YYYashushi Yoshino
Yashushi Yoshino
SIShohei Ishida
Shohei Ishida
TFTakashi Fujita
Takashi Fujita
TMTsuyoshi Majima
Tsuyoshi Majima
MGMomokazu Gotoh
Momokazu Gotoh

1 December 2009 in Journal of Urology
Verified
Journal Article
Closed access
YMYoshihisa Matsukawa
Yoshihisa Matsukawa
MGMomokazu Gotoh
Momokazu Gotoh
TKTomonori Komatsu
Tomonori Komatsu
YFYasuhito Funahashi
Yasuhito Funahashi
NSNaoto Sassa
Naoto Sassa
RHRyohei Hattori
Ryohei Hattori
We investigated the effect of the new sympathetic alpha1A-adrenoceptor antagonist silodosin for relieving benign prostatic obstruction by pressure flow study. In this open, nonblinded, prospective study we administered 8 mg silodosin daily for 4 weeks in 60 patients with lower urinary tract symptoms associated with benign prostatic enlargement. As a primary outcome measure, we assessed changes in bladder function and benign prostatic obstruction using pressure flow study. As secondary outcome measures, changes in subjective symptoms and quality of life were assessed by the International Prostate Symptom Score. Objective changes in urination status were also assessed by free uroflowmetry in terms of maximum flow rate and post-void residual urine volume. A total of 57 patients were enrolled for analysis. In the storage phase of the pressure flow study bladder capacity at first desire to void increased significantly with no significant change in maximum cystometric capacity. Of 24 patients 14 (58.3%) with uninhibited detrusor contractions before administration showed apparent improvement in detrusor overactivity after administration, including 6 in whom uninhibited contractions disappeared. In the voiding phase mean detrusor pressure at maximum flow significantly decreased from 72.5 to 51.4 cm H(2)O. The mean bladder outlet obstruction index decreased significantly from 60.6 to 33.8. Obstruction grade assessed by the Schaefer nomogram improved in all except 1 patient. Total symptom and quality of life scores, maximum flow rate and post-void residual urine volume on free uroflowmetry significantly improved. Silodosin improved lower urinary tract symptoms by improving bladder storage function and relieving benign prostatic obstruction.

21 September 2019 in International Journal of Urology
Verified
Journal Article
Closed access
PDF file
YMYoshihisa Matsukawa
Yoshihisa Matsukawa
MYMasaki Yoshida
Masaki Yoshida
OYOsamu Yamaguchi
Osamu Yamaguchi
STShun Takai
Shun Takai
TMTsuyoshi Majima
Tsuyoshi Majima
MGMomokazu Gotoh
Momokazu Gotoh

21 June 2010 in International Journal of Urology
Verified
Journal Article
Closed access
PDF file
YMYoshihisa Matsukawa
Yoshihisa Matsukawa
RHRyohei Hattori
Ryohei Hattori
TKTomonori Komatsu
Tomonori Komatsu
YFYasuhito Funahashi
Yasuhito Funahashi
NSNaoto Sassa
Naoto Sassa
MGMomokazu Gotoh
Momokazu Gotoh

11 June 2020 in LUTS: Lower Urinary Tract Symptoms
Verified
Journal Article
Closed access
PDF file
MYMakoto Yono
Makoto Yono
KIKazuya Ito
Kazuya Ito
MOMegumi Oyama
Megumi Oyama
TTTakanori Tanaka
Takanori Tanaka
SIShin Irie
Shin Irie
OYOsamu Yamaguchi
Osamu Yamaguchi

1 April 2015 in Urology
Verified
Journal Article
Closed access
YMYoshihisa Matsukawa
Yoshihisa Matsukawa
STShun Takai
Shun Takai
YFYasuhito Funahashi
Yasuhito Funahashi
TYTokunori Yamamoto
Tokunori Yamamoto
MGMomokazu Gotoh
Momokazu Gotoh